id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2014-0006,FDA,FDA-2022-E-2014,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T16:54:59Z,,0,0,09000064863e55bb
FDA-2022-E-2014-0008,FDA,FDA-2022-E-2014,Letter from U.S. Patent and Trademark Office to Dr. Chad E. Davis,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T17:00:09Z,,0,0,090000648648c9d5
FDA-2022-E-2014-0007,FDA,FDA-2022-E-2014,Interim Extension Letter from U.S. Patent and Trademark Office to Goodwin Procter LLP,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T16:56:09Z,,0,0,0900006486440079